APOE and Alzheimer disease: Nonetheless, the use of this biomarker could significantly diminish the required Aβ-PET scans in clinical trial participant recruitment [51], especially if using an algorithm that includes APOE proteotype and age [52] and help clinicians in making decisions about AD diagnosis and pharmacological management [53].